Gilead Q3 2026 Revenue Rises 6.8% to $8.3 Billion
Gilead reported Q3 2026 revenue of $8.3 billion, up 6.8% year over year. Its full-year revenue guidance midpoint of $31.15 billion was 1.3% above analysts’ consensus.
Biopharmaceutical company Gilead Sciences NASDAQ:GILDbeat Wall Street’s revenue expectations in Q3 2026, with revenue up 6.8% year on year to $8.3 billion. The company’s full-year revenue guidance of $31.15 billion at the midpoint came in 1.3% above analysts’ consensus estimates. Its non-GAAP profi…